Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging studies in movement disorders.

John P Seibyl1

  • 1Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA.

Seminars in Nuclear Medicine
|May 21, 2003
PubMed
Summary

Imaging presynaptic dopaminergic markers are crucial for Parkinson

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflamed Microglia like Macrophages in the Central Nervous System of Prodromal Parkinson's Disease.

bioRxiv : the preprint server for biology·2025
Same author

Characterizing Parkinson's Disease Clinical and Biomarker Interactions in REM Sleep Behavior Disorder.

medRxiv : the preprint server for health sciences·2025
Same author

α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2023
Same author

Neurotheranostics: The Next Frontier for Health Span.

Journal of nuclear medicine technology·2023
Same author

Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2022
Same author

A Visual Interpretation Algorithm for Assessing Brain Tauopathy with <sup>18</sup>F-MK-6240 PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2022

Area of Science:

  • Neuroimaging
  • Neurodegenerative Diseases
  • Parkinson's Disease Pathophysiology

Background:

  • Presynaptic dopaminergic imaging is vital for understanding Parkinson's Disease (PD) and evaluating therapies.
  • Current imaging targets require optimization for reliable disease progression measurement.
  • PD involves widespread neurodegeneration beyond the dopamine system.

Purpose of the Study:

  • To explore the optimization of imaging targets for Parkinson's Disease progression.
  • To investigate the potential of characterizing PD patients (e.g., slow vs. fast progressors) using imaging.
  • To consider additional non-dopaminergic imaging targets for improved disease characterization and therapeutics.

Main Methods:

  • Review and synthesis of current literature on dopaminergic imaging in PD.
  • Conceptual framework for optimizing imaging endpoints in clinical trials.
  • Exploration of non-dopaminergic imaging strategies for PD.

Main Results:

  • Optimized imaging markers can enhance the accuracy of PD progression assessment.
  • Patient stratification based on imaging can refine clinical trial recruitment and interpretation.
  • Non-dopaminergic imaging may reveal broader pathological mechanisms and therapeutic targets in PD.

Conclusions:

  • Advancements in presynaptic dopaminergic imaging are essential for PD clinical trials.
  • Tailoring trial recruitment using imaging biomarkers can improve therapeutic evaluation.
  • Expanding imaging to non-dopaminergic systems holds promise for a comprehensive understanding and treatment of PD.

Related Experiment Videos